Clinical Report: FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Overview

Dupilumab (Dupixent) has been approved by the FDA for the treatment of allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older who have undergone sinonasal surgery or for whom surgery is not advisable.

Background

Allergic fungal rhinosinusitis is a subtype of chronic rhinosinusitis characterized by an allergic response to fungal organisms. It affects up to 8% of patients with chronic sinus inflammation, is more prevalent in warm, humid climates, and can lead to severe complications, including bone erosion and visual impairment.

Data Highlights

Key Findings

• Dupilumab is the first FDA-approved therapy specifically for AFRS.
• Significant improvement in sinus opacification was observed at 52 weeks.
• Dupilumab reduced the need for systemic corticosteroids and sinus surgery compared to placebo.
• Improvements in nasal polyp size, nasal congestion, and olfactory function were also observed.
• In pediatric patients, efficacy was extrapolated from adult data with similar disease pathophysiology.
• The safety profile of dupilumab was consistent with previous findings in chronic rhinosinusitis with nasal polyps.

Clinical Implications

Healthcare providers can now offer dupilumab as a targeted therapy for patients with AFRS, potentially reducing the need for invasive procedures. Monitoring for common adverse reactions, such as injection-site reactions, eosinophilia, insomnia, toothache, gastritis, and arthralgia, will be essential in managing patient care.

Conclusion

The approval of dupilumab represents a significant advancement in the management of allergic fungal rhinosinusitis, providing a new therapeutic option that addresses both symptoms and underlying disease mechanisms.

References

1. FDA, FDA, 2026 -- FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis
2. POSITION PAPER: EPOS2020, Rhinology Journal, 2020 -- EPOS2020 Executive Summary
3. conexiant — Pediatric Allergic Rhinitis: When Meds Fall Short
4. Contact Lens Spectrum — Dry Eye Dx and Tx
5. Ophthalmology Management — Can Allergy Drops Improve Nasal Symptoms?
6. Ophthalmology Management — RX PERSPECTIVE
7. POSITION PAPER: EPOS2020
8. FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis | FDA